PARITHERA
Precision oncology includes new ways of treating cancer such as targeted therapies and immunotherapies. These approaches are more specific and effective than current treatments. In the near future, they will considerably reduce worldwide cancer burden. As of today, only a fraction of the 18 million yearly diagnosed patients benefit from precision oncology. To increase the number of beneficiaries, new diagnostic tools are needed to match the specific needs of precision oncology to define patients' eligibility and monitor treatment response.
PARITHERA
Social Links:
Industry:
Therapeutics
Founded:
2021-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.parithera.com
Total Employee:
1+
Status:
Active
Total Funding:
100 K CHF
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Amazon Google Apps For Business Microsoft Azure DNS Google
Similar Organizations
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Founder
Investors List
École Polytechnique Fédérale de Lausanne
École Polytechnique Fédérale de Lausanne investment in Grant - Parithera
Official Site Inspections
http://www.parithera.com
- Host name: 185.158.133.1
- IP address: 185.158.133.1
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Parithera"
Parithera - Crunchbase Company Profile & Funding
Precision oncology includes new ways of treating cancer such as targeted therapies and immunotherapies.See details»
Parithera - ExPlore - Precision Oncology
Initial response Following treatment, the tumor shrinks as most cells respond. However, evolutionary pressure gives rise to resistant clones—the blue (intrinsic) and the orange …See details»
Parithera - LinkedIn
Parithera ’s new website will introduce two breakthrough platforms – ExTrace and ExPlore – built to capture and decode tumor heterogeneity with unmatched precision.See details»
Parithera - Products, Competitors, Financials, Employees, …
About Parithera Parithera develops medical device to detect cancer treatment resistance. It provides a minimally invasive, inexpensive, and actionable cancer diagnosis platform to guide …See details»
Parithera 2025 Company Profile: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for Parithera. Use the PitchBook Platform to explore the full profile.See details»
Parithera • Biopôle
Parithera’s goal is to save lives by providing a minimally invasive diagnostic which analyses cancer treatment resistance and allows clinicians to adjust treatment regimen. Activity or …See details»
Parithera - VentureRadar
Parithera’s innovative approach is based on two inventions in the domain of CTC isolation and sequencing preparation. Parithera’s goal is to save lives by providing a minimally invasive …See details»
Parithera SA - Swiss Biotech
Parithera is pioneering an AI-ready, clinical-grade liquid biopsy platform for single-cell analysis. Our platform is ideally positioned to study cancer treatment resistance.See details»
Parithera - Funding, Financials, Valuation & Investors
Parithera is funded by 2 investors. Biopôle and Federal Polytechnic School of Lausanne are the most recent investors.See details»
Parithera SA - Venture Kick
Sep 5, 2022 Incorporated: 30.06.2021 Headquarter: Epalinges Support: Medtech Cancer Diagnostics Nano technologies Medical devices Medtech Patient monitoringParithera SA:See details»
Parithera - Sesamers
Company Description Parithera is a US-Swiss startup aiming to revolutionize drug discovery through our AI platform. Our proprietary hardware generates unique biological data that …See details»
Rapid early detection of drug resistance in cancer patients
Jun 10, 2023 Parithera, an EPFL spin-off, has developed a system that lets doctors detect drug resistance in cancer patients early on, saving precious time and preventing the unnecessary …See details»
Parithera - Crunchbase
Parithera, Avstera Therapeutics, Verismo Therapeutics, Oncora Medical, Pinpoint Therapeutics, and Vivodyne are all involved in the oncology and biotech sector. Avstera and Verismo focus …See details»
Parithera - BioAlps
Develops a new generation of CTC (Cancer Tumor Cells) liquid biopsy to isolate more CTCs with a high purity in a faster way than any marketed solution.See details»
Parithera - Contacts, Employees, Board Members, Advisors & Alumni
Parithera has 2 current employee profiles, including CEO & Co-founder Antoine Herzog.See details»
Parithera SA - startupticker.ch
Parithera SA specializes in the development of a platform for the clinical single cell sequencing of rare cells. Paritheras breakthrough technologies enable the development of the first walk-away …See details»
Parithera: A drug detection system for cancer patients - LinkedIn
Parithera, an #EPFLstartup, has developed a system that lets doctors detect drug resistance in cancer patients early on. This could revolutionize the way…See details»
Parithera SA - Venture Kick
Parithera SA: Parithera’s goal is to save lives by providing a non-invasive diagnostic which analyses cancer treatment resistance and allows clinicians to adjust treatment regimen. As of …See details»
Parithera SA - startup.ch
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in …See details»
Parithera raises CHF 100 000 from FIT - BioAlps
Mar 21, 2025 The Foundation for Technological Innovation (FIT) has granted a CHF 100’000 Tech Seed loan to Parithera and its ExTrace Dx solution for cancer treatment. 90% of patients …See details»